Document Detail


Management of anemia in the newborn.
MedLine Citation:
PMID:  18640796     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Red blood cell (RBC) transfusions are administered to neonates and premature infants using poorly defined indications that may result in unintentional adverse consequences. Blood products are often manipulated to limit potential adverse events, and meet the unique needs of neonates with specific diagnoses. Selection of RBCs for small volume (5-20 mL/kg) transfusions and for massive transfusion, defined as extracorporeal bypass and exchange transfusions, are of particular concern to neonatologists. Mechanisms and therapeutic treatments to avoid transfusion are another area of significant investigation. RBCs collected in anticoagulant-additive solutions and administered in small aliquots to neonates over the shelf life of the product can decrease donor exposure and has supplanted the use of fresh RBCs where each transfusion resulted in a donor exposure. The safety of this practice has been documented and procedures established to aid transfusion services in ensuring that these products are available. Less well established are the indications for transfusion in this population; hemoglobin or hematocrit alone are insufficient indications unless clinical criteria (e.g. oxygen desaturation, apnea and bradycardia, poor weight gain) also augment the justification to transfuse. Comorbidities increase oxygen consumption demands in these infants and include bronchopulmonary dysplasia, rapid growth and cardiac dysfunction. Noninvasive methods or assays have been developed to measure tissue oxygenation; however, a true measure of peripheral oxygen offloading is needed to improve transfusion practice and determine the value of recombinant products that stimulate erythropoiesis. The development of such noninvasive methods is especially important since randomized, controlled clinical trials to support specific practices are often lacking, due at least in part, to the difficulty of performing such studies in tiny infants.
Authors:
Naomi L C Luban
Related Documents :
19419506 - Protein-energy malnutrition as the first manifestation of cystic fibrosis in infancy.
10363856 - Comparing alloimmunization in preterm infants after transfusion of fresh unmodified ver...
22254056 - Effect of long-chain polyunsaturated fatty acid supplementation on neurodevelopmental o...
3513096 - Anemia of prematurity. current concepts in the issue of when to transfuse.
9467696 - Posture, spontaneous movements, and behavioural state organisation in infants affected ...
15230716 - Surgical treatment of temporoparietooccipital cortical dysplasia in infants: report of ...
Publication Detail:
Type:  Journal Article; Practice Guideline; Review     Date:  2008-07-21
Journal Detail:
Title:  Early human development     Volume:  84     ISSN:  0378-3782     ISO Abbreviation:  Early Hum. Dev.     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-18     Completed Date:  2008-10-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7708381     Medline TA:  Early Hum Dev     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  493-8     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, The George Washington University School of Medicine, United States. nluban@cnmc.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / blood,  diagnosis,  etiology,  therapy*
Erythrocyte Transfusion* / adverse effects,  methods,  standards
Humans
Infant, Newborn
Infant, Premature
Randomized Controlled Trials as Topic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genetic differences among Staphylococcus aureus isolates from dairy ruminant species: a single-dye D...
Next Document:  Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro...